The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation
The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation
复制标题
DOI：
10.1093/annonc/mdf228
复制
发表时间：
2002-09-01
影响因子：
50.5
通讯作者：
Armitage, JO
中科院分区：
文献类型：
--
作者：
Bierman, PJ;Lynch, JC;Armitage, JO
背景资料：国际晚期霍奇金病预后因素项目为接受化疗的新诊断霍奇金病患者开发了一种七因素预后评分，包括血清白蛋白、血红蛋白、性别、分期、年龄、白细胞增多和淋巴细胞减少。本研究的目的是确定这种预后评分是否也适用于接受自体造血干细胞移植的霍奇金病患者。我们对379例接受自体移植治疗霍奇金病的患者进行了回顾性分析，对1984年10月至1999年12月间在内布拉斯加大学医学中心接受的20例乳腺癌患者进行了多变量分析，以确定国际标准中确定的预后因素是否结果：低血清白蛋白、贫血、年龄、淋巴细胞减少与无事件生存期（EFS）和总生存期（OS）相关，性别、分期、白细胞增多与无事件生存期（EFS）和总生存期（OS）无关。国际预后因素项目（International Prognostic Factors Project）确定的具有0-1、2-3或大于或等于4个不良预后特征的患者的10年EFS估计值分别为38%、2- 3%和7%。晚期疾病的预后评分也适用于接受高剂量化疗的复发性和难治性霍奇金病患者。剂量治疗后进行自体造血干细胞移植。
Background: The International Prognostic Factors Project on Advanced Hodgkin's Disease developed a seven-factor prognostic score consisting of serum albumin, hemoglobin, gender, stage, age, leukocytosis and lymphocytopenia for newly diagnosed Hodgkin's disease patients who receive chemotherapy. The purpose of this study was to determine whether this prognostic score would also be useful for Hodgkin's disease patients undergoing autologous hematopoietic stem cell transplantation.Patients and methods: We performed a retrospective review of 379 patients who had autologous transplants for Hodgkin's disease, at the University of Nebraska Medical Center between October 1984 and December 1999 Multivariate analysis was performed to determine whether the prognostic factors identified by the International Prognostic Factors Project adversely influenced event-free survival (EFS) or overall survival (OS).Results: Low serum albumin, anemia, age and lymphocytopenia were associated with poorer EFS and OS. Gender, stage and leukocytosis were not associated with significantly poorer outcomes. Estimated 10-year EFS was 38%, 23% and 7% for patients with 0-1, 2-3 or greater than or equal to4 of the adverse prognostic characteristics identified by the International Prognostic Factors Project, respectively.Conclusions: The prognostic score for advanced disease is also useful for relapsed and refractory Hodgkin's disease patients undergoing high-dose therapy followed by autologous hematopoietic stein cell transplantation.